Protein-reactive metabolites of carbamazepine in mouse liver microsomes.
The character of reactive metabolites formed from carbamazepine (CBZ) was sought in incubations of [14C]CBZ in hepatic microsomes prepared from adult female mice of a strain (SWV/Fnn) susceptible to CBZ-induced teratogenicity. The formation of radio-labeled protein adducts was used as an index of reactive metabolite exposure. A dependence on cytochrome P450 was shown by a requirement for NADPH and inhibition by carbon monoxide, 1-aminobenzotriazole, piperonyl butoxide, and stiripentol. The addition of ascorbic acid, caffeic acid, N-acetylcysteine, and glutathione decreased the rate of binding of the radiolabel from [14C]CBZ to microsomal protein by more than 50%. The addition of glutathione transferases diminished protein adduct formation beyond that seen with glutathione alone. Evidence for the formation of an arene oxide was sought through the use of inhibitors of epoxide hydrolases, including cyclohexene oxide, chalcone oxides (with the addition of cytosol as appropriate), and by the addition of recombinant human soluble and microsomal epoxide hydrolases and recombinant rat microsomal epoxide hydrolase. The microsomal epoxide hydrolases decreased the velocity of 14C-labeled protein adduct formation by approximately 23%, whereas inhibitors had no effect, most likely because of the low native activity of microsomal epoxide hydrolase in mice. Both DT-diaphorase and catechol-O-methyltransferase diminished 14C-labeled protein adduct formation by 54% and 45%, respectively. The data suggest that the major reactive metabolites formed from CBZ by adult female SWV/Fnn liver microsomes are quinones and arene oxides.
Lillibridge
J H
JH
Department of pharmaceutics, University of Washington, Seattle, WA 98195-7610, USA.
Amore
B M
BM
Slattery
J T
JT
Kalhorn
T F
TF
Nelson
S D
SD
Finnell
R H
RH
Bennett
G D
GD
D000818:Animals; D000927:Anticonvulsants / Q000378:metabolism; D001205:Ascorbic Acid / Q000494:pharmacology; D002109:Caffeic Acids / Q000494:pharmacology; D002220:Carbamazepine / Q000378:metabolism*; D002248:Carbon Monoxide / Q000494:pharmacology; D002394:Catechol O-Methyltransferase / Q000378:metabolism; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004148:Dioxolanes / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004851:Epoxide Hydrolases / Q000037:antagonists & inhibitors / Q000378:metabolism; D005260:Female; D005982:Glutathione Transferase / Q000378:metabolism; D051379:Mice; D008815:Mice, Inbred Strains; D008862:Microsomes, Liver / Q000737:chemistry / Q000378:metabolism*; D016660:NAD(P)H Dehydrogenase (Quinone) / Q000378:metabolism; D009249:NADP / Q000378:metabolism / Q000494:pharmacology; D010882:Piperonyl Butoxide / Q000494:pharmacology; D013438:Sulfhydryl Compounds / Q000494:pharmacology; D014230:Triazoles / Q000494:pharmacology
D000927:Anticonvulsants; D002109:Caffeic Acids; D065607:Cytochrome P-450 Enzyme Inhibitors; D004148:Dioxolanes; D004791:Enzyme Inhibitors; D013438:Sulfhydryl Compounds; D014230:Triazoles; C033020:1-aminobenzotriazole; D002220:Carbamazepine; D009249:NADP; D002248:Carbon Monoxide; D003577:Cytochrome P-450 Enzyme System; D016660:NAD(P)H Dehydrogenase (Quinone); D002394:Catechol O-Methyltransferase; D005982:Glutathione Transferase; D004851:Epoxide Hydrolases; D010882:Piperonyl Butoxide; D001205:Ascorbic Acid; C021092:stiripentol; C040048:caffeic acid